REGENXBIO, Inc.

REGENXBIO, Inc.

REGENXBIO, Inc.

Overview
Date Founded

2008

Headquarters

9600 Blackwell Road,Suite 210,Rockville, MD 20850

Type of Company

Public

Employees (Worldwide)

257

Industries

Biotechnology
Pharmaceuticals

Company Description

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Contact Data
Trying to get in touch with decision makers at REGENXBIO, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Scientific Founder

President, Chief Executive Officer, Executive Director

Senior Vice President, Chief Financial Officer & Principal Accounting Officer

Senior Vice President & General Counsel

Senior Vice President & Chief Scientific Officer

Senior Vice President & Chief Medical Officer

Senior Vice President, Intellectual Property

Senior Vice President, Human Resources

Senior Vice President, Chief Operations & Technology Officer

Senior Vice President-Commercial Strategy & Operations

Board of Directors

Co-Founder at Dimension Therapeutics, Inc.

Former Executive Vice President & Chief Financial Officer at Cambrex Corp.

Former President & Chief Executive Officer at Emergent BioSolutions, Inc.

Venture Partner at Apple Tree Partners

Chief Executive Officer & Executive Director at DBV Technologies

Consultant at Sunesis Pharmaceuticals, Inc.

President, Chief Executive Officer & Director at Cedilla Therapeutics, Inc.

Paths to REGENXBIO, Inc.
Potential Connections via
Relationship Science
You
REGENXBIO, Inc.
Owners & Shareholders
Details Hidden

Redmill invests in US and non-US healthcare companies. They may also invest in fields related to healthcare where due diligence shows that healthcare assets are the driving force behind value creation and in other sectors from time to time. The firm uses the fundamental research as part of their investment process. Their protocols include company financial models; market models; investment theses; and regular dialogue. Redmill’s sources include contacts with physicians; focus outside US; dialogue with companies; attendance at medical conferences; meetings with private companies; and regular dialogue within the team.

Details Hidden

Aquilo Capital Management focuses on long/short investments in the stocks of companies in the life sciences and biotechnology sectors

Details Hidden

Goldstein & McClintock LLLP is a cutting-edge boutique law firm representing a broad array of sophisticated clients in a wide variety of matters across the nation. In addition to handling all aspects of corporate restructuring matters through its pre-eminent corporate restructuring, bankruptcy, and creditors’ rights practice, G&M attorneys regularly assist clients with a wide variety of transactional and commercial litigation matters. G&M’s partners – all of whom have worked on numerous complex matters, including at some of the top corporate law firms in the U.S. – are well known in both the regional and national bankruptcy bar, and have represented a host of constituencies in some of the country’s most significant cases. Whatever the matter, G&M is unique in being able to offer clients affordable “white-shoe” advice combined with the accessibility and individual attention of a boutique law practice. Although G&M's attorneys are well versed in a broad spectrum of matters – from corporate, finance, and real estate transactions to commercial litigation cases – G&M routinely receives accolades for its extensive restructuring and bankruptcy practice. G&M's restructuring professionals have extensive experience in workout negotiations, reorganizations, bankruptcy litigation, and debtor-creditor relations. Whether it is an out-of-court restructuring, workout advice, pre-bankruptcy counseling and planning, guidance through the chapter 11 process, or building leverage to maximize value for creditors, G&M's ability to provide top-tier counsel at affordable prices is without parallel.

Recent Transactions
Details Hidden

REGENXBIO, Inc. issued USD Common Stock

Details Hidden

REGENXBIO, Inc. issued USD Common Stock

Details Hidden

REGENXBIO, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onREGENXBIO, Inc. issued USD Common Stock

Underwriter

Advised onREGENXBIO, Inc. issued USD Common Stock

Auditor

Advised onREGENXBIO, Inc. issued USD Common Stock

Professional

Advised onREGENXBIO, Inc. issued USD Common Stock

Legal Advisor

Advised onREGENXBIO, Inc. issued USD Common Stock

Underwriter

Advised onREGENXBIO, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Davis Polk & Wardwell LLP

Legal Advisor

Partner at Davis Polk & Wardwell LLP

Clients

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Key Stats and Financials As of 2019
Market Capitalization
$1.76B
Total Enterprise Value
$1.22B
Earnings Per Share
$-2.58
Revenue
$35.2M
EBITDAMargin
-402.59%
EBITDA
$-142M
Total Debt
$11.3M
Total Equity
$450M
Net Profit
$-94.7M
Enterprise Value / Sales
34.58x
TEVNet Income
-12.86x
Debt TEV
0.01x
Three Year Compounded Annual Growth Rate Of Revenue
97.28%
Non-Profit Donations & Grants
$50K +
2018
$500 - $999
2017
$1,000 - $2,999
2015
Investments
Details Hidden

Dimension Therapeutics, Inc. engages in the provision of medical development. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz on October 2013, and is headquartered in Cambridge, MA.

Investors
Details Hidden

Deerfield Management Co. LP invests in companies located in the US. The firm target companies operating in broad range of industries. They provides financing for buyout transactions to private and public.

Details Hidden

Cormorant invests in companies primarily located in North America. The firm targets companies in sectors such as life-science and biotech. It provides financing for early stage capital requirements.

Details Hidden

NIH is the largest source of funding for medical research in the world, creating hundreds of thousands of high-quality jobs by funding thousands of scientists in universities and research institutions in every state across America and around the globe. NIH is made up of 27 Institutes and Centers, each with a specific research agenda, often focusing on particular diseases or body systems. NIH leadership plays an active role in shaping the agency's research planning, activities, and outlook. The Office of the Director is the central office at NIH, responsible for setting policy for NIH and for planning, managing, and coordinating the programs and activities of all the NIH components. The NIH Director, with a unique and critical perspective on the entire agency, is responsible for providing leadership to the Institutes and for constantly identifying needs and opportunities, especially for efforts that involve multiple Institutes. The NIH Director is assisted by the NIH Deputy Directors including the Principal Deputy Director, who shares in the overall direction of the agency's activities. NIH is responsive to Congressional legislation that adjusts NIH's programs to meet changing research needs. As a result of the NIH reauthorization process, NIH is able to respond strategically in an era when medical research requires constant innovation and increased interdisciplinary efforts. More than 80% of the NIH's budget goes to more than 300,000 research personnel at over 2,500 universities and research institutions. In addition, about 6,000 scientists work in NIH’s own Intramural Research laboratories, most of which are on the NIH main campus in Bethesda, Maryland. The main campus is also home to the NIH Clinical Center, the largest hospital in the world totally dedicated to clinical research. Successful biomedical research depends on the talent and dedication of the scientific workforce. NIH supports many innovative training programs and funding mechanisms that foster scientific creativity and exploration. The goal is to strengthen our nation’s research capacity, broaden our research base, and inspire a passion for science in current and future generations of researchers. NIH encourages and depends on public involvement in federally supported research and activities. NIH’s wide-ranging public efforts include outreach and education, nationwide events, requests for public input on NIH projects, and special programs designed specifically to involve public representatives in clinical research

Suppliers
GlaxoSmithKline Plc Medical Support Services | Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

University of Pennsylvania Computer Software | Philadelphia, PA

The University of Pennsylvania (commonly referred to as Penn or UPenn) is a private, Ivy League university, located in Philadelphia, Pennsylvania, United States. Penn considers itself the fourth-oldest institution of higher education in the United States, as well as the first university in the United States with both undergraduate and graduate studies.

FUJIFILM Holdings Corp. Equipment & Office Supplies | Tokyo, Japan

FUJIFILM Holdings, Inc. engages in the development, production, sales and service of imaging, information, and document solutions. It operates through the following segments: Imaging Solutions, Information Solutions, and Document Solutions. The Imaging Solutions segment handles color films, digital cameras, optical devices, color paper, services and equipment for photofinishing, instant photo systems, etc. The Information Solutions segment deals with the equipment and materials for medical systems, life sciences products, pharmaceuticals, graphic arts, flat panel display materials, recording media and electronic materials, etc. The Document Solutions segment provides office copy machines/MFPs, printers, production systems and services, office services, paper and consumables, etc. The company was founded on January 20, 1934 and is headquartered in Tokyo, Japan.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by REGENXBIO, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of REGENXBIO, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and REGENXBIO, Inc..